Lazard Asset Management
RXRX icon

Lazard Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Lazard Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54M Buy
692,378
+291,616
+73% +$971K ﹤0.01% 876
2026
Q1 		$1.23M Sell
400,762
-19,244
-5% -$74.4K ﹤0.01% 1098
2025
Q4 		$1.72M Sell
420,006
-75,158
-15% -$372K ﹤0.01% 936
2025
Q3 		$2.42M Buy
495,164
+90,800
+22% +$477K ﹤0.01% 798
2025
Q2 		$2.05M Sell
404,364
-101,774
-20% -$500K ﹤0.01% 1014
2025
Q1 		$2.68M Sell
506,138
-49,712
-9% -$362K ﹤0.01% 874
2024
Q4 		$3.76M Sell
555,850
-86,458
-13% -$581K 0.01% 708
2024
Q3 		$4.23M Buy
642,308
+118,150
+23% +$847K 0.01% 679
2024
Q2 		$3.93M Buy
524,158
+243,490
+87% +$2.12M ﹤0.01% 738
2024
Q1 		$2.8M Sell
280,668
-91,031
-24% -$1.01M ﹤0.01% 787
2023
Q4 		$3.66M Buy
371,699
+36,675
+11% +$262K ﹤0.01% 741
2023
Q3 		$2.56M Sell
335,024
-10,099
-3% -$101K ﹤0.01% 830
2023
Q2 		$2.58M Sell
345,123
-417
-0.1% -$2.92K ﹤0.01% 843
2023
Q1 		$2.3M Buy
345,540
+181,631
+111% +$1.44M ﹤0.01% 891
2022
Q4 		$1.26M Sell
163,909
-140,303
-46% -$1.38M ﹤0.01% 976
2022
Q3 		$3.24M Buy
304,212
+14,603
+5% +$148K ﹤0.01% 793
2022
Q2 		$2.36M Buy
289,609
+100,685
+53% +$674K ﹤0.01% 870
2022
Q1 		$1.35M Buy
188,924
+45,540
+32% +$484K ﹤0.01% 959
2021
Q4 		$2.46M Buy
+143,384
New +$2.7M ﹤0.01% 898

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Lazard Asset Management's RXRX Position: Q2 2026 in Review

Lazard Asset Management increased its Recursion Pharmaceuticals (RXRX) stake by 73% in Q2 2026, buying an estimated $971K and bringing the position to 692,378 shares worth $2.54M. The position accounts for ﹤0.01% of the portfolio, ranked #876.

Lazard Asset Management first reported a position in RXRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $4.23M in Q3 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Lazard Asset Management held 692,378 shares of Recursion Pharmaceuticals worth $2.54M as of Q2 2026.
  • Lazard Asset Management bought 291,616 Recursion Pharmaceuticals shares in Q2 2026, an estimated $971K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #876 holding.
  • Lazard Asset Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • Lazard Asset Management's Recursion Pharmaceuticals position peaked at $4.23M in Q3 2024.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.